Aura Biosciences

Aura Biosciences, based in Boston, MA, the United States, is a biotechnology company. Aura Biosciences is a clinical-stage biotechnology company developing targeted oncology therapies for ocular cancers using its proprietary Virus-Like Drug Conjugate (VDC) technology. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing AU-011 in melanoma and uveal melanoma. The largest, NCT06007690 (A Phase 3 Randomised, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma), plans to enrol 108 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.